3-(1H-1,3-benzodiazol-2-yl)benzoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-(1H-1,3-benzodiazol-2-yl)benzoic acid
• 英文别名: 3-(1H-benzo[d]imidazol-2yl)benzoic acid；3-(1H-benzimidazol-2-yl)benzoic acid；3-(1H-benzoimidazol-2-yl)benzoic acid；3-(1H-benzimidazol-1-ium-2-yl)benzoate
• 化学式: C₁₄H₁₀N₂O₂
• mdl: MFCD02323224
• 分子量: 238.246
• InChiKey: BQKXFNQLZLSSEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(1H-1,3-benzodiazol-2-yl)benzoic acid 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成
  参考文献：
  名称：

  LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS

  摘要：

  提供了针对蓝曲氨酸合成酶C样蛋白2途径的化合物。这些化合物可用于治疗多种疾病，包括传染病、自身免疫疾病、糖尿病和慢性炎症性疾病。

  公开号：

  US20160115153A1
• 作为产物：
  描述：

  3-(1H-benzo[d]imidazol-2-yl)benzonitrile 在 sodium hydroxide 作用下， 生成 3-(1H-1,3-benzodiazol-2-yl)benzoic acid
  参考文献：
  名称：

  Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury

  摘要：

  A novel series of benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines were designed and synthesized as Na+/H(+)exchanger inhibitors. Most of them were found to inhibit NHE1-mediated platelet swelling in a concentration-dependent manner, and to have significant cardioprotective effect against myocardial ischemic-reperfusion injury, among which compounds 10a and 34 were more potent than cariporide in both in vivo and in vitro tests. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.035

文献信息

• Novel compounds useful for bradykinin B1 receptor antagonism
  申请人：Ye Michael Xiaocong

  公开号：US20070032475A1

  公开（公告）日：2007-02-08

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor.

  揭示了一种化合物，它们是布雷金肽B1受体拮抗剂，可用于治疗或缓解由布雷金肽B1受体介导的哺乳动物疾病，或与疾病状况相关的不良症状。
• Metal–organic framework mediated expeditious synthesis of benzimidazole and benzothiazole derivatives through an oxidative cyclization pathway
  作者：Velayudham Sankar、Peramaiah Karthik、Bernaurdshaw Neppolian、Bitragunta Sivakumar

  DOI：10.1039/c9nj04431k

  日期：——

  report the facile synthesis of various benzimidazoles and benzothiazoles by using the NH2-MIL-125(Ti) MOF as an efficient oxidant-free heterogeneous catalyst with good yield. Adsorption of the substrate on the NH2-MIL-125(Ti) MOF surface through electron deficient Ti4+ sites initiates the reaction. The broad substrate scope and high reusability of this catalyst are attractive for synthesis of a wide range

  本文中，我们报道了使用NH 2 -MIL-125（Ti）MOF作为一种高效，无氧化剂，产率高的方法，可以轻松合成各种苯并咪唑和苯并噻唑。底物通过缺电子的Ti 4+位点在NH 2 -MIL-125（Ti）MOF表面上的吸附引发了反应。该催化剂的广泛的底物范围和高的可重复使用性对于合成多种医学活性的苯并咪唑和苯并噻唑衍生物是有吸引力的。
• Lanthionine synthetase C-like 2-based therapeutics
  申请人：Landos Biopharma, Inc.

  公开号：US10028950B2

  公开（公告）日：2018-07-24

  Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

  本研究提供了以兰硫宁合成酶 C 样蛋白 2 通路为靶点的化合物。这些化合物可用于治疗多种疾病，包括传染病、自身免疫性疾病、糖尿病和慢性炎症性疾病。
• Compositions and methods for blocking sodium channels
  申请人：University of Virginia Patent Foundation

  公开号：US11090289B2

  公开（公告）日：2021-08-17

  The disclosure provides methods for treating a subject suffering from a disease associated with sodium channel activity. The method comprises administering to the subject a therapeutically effective amount of a compound according to Formula II or Formula III described in the specification, or a pharmaceutically acceptable salt, prodrug, tautomer, stereoisomer, hydrate, or solvate thereof.

  本公开提供了治疗患有与钠通道活性相关疾病的受试者的方法。该方法包括向受试者施用治疗有效量的根据说明书所述式 II 或式 III 的化合物，或其药学上可接受的盐、原药、同系物、立体异构体、水合物或溶液。
• An <i>N</i>,<i>N</i>-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease
  作者：Adria Carbo、Richard D. Gandour、Raquel Hontecillas、Noah Philipson、Aykut Uren、Josep Bassaganya-Riera

  DOI：10.1021/acs.jmedchem.6b00412

  日期：2016.11.23

  Lanthionine synthetase C-like 2 (LANCL2), a novel therapeutic target for inflammatory and autoimmune diseases and diabetes, exerts anti-inflammatory and insulin-sensitizing effects. This study reports the first LANCL2-based therapeutics for inflammatory bowel disease (IBD). Analogues of 1 (ABA) and 2 (NSC61610) were screened by molecular docking, then synthesized and analyzed for binding to LANCL2 by surface plasmon resonance. Piperazine-1,4-diylbis(6-benzo[d]imidazole-2-yl)pyridine-2-yl(methanone, 7, was identified as the lead LANCL2-binding compound for treating IBD. The oral treatment with 7 (8 mg/kg/d) in a mouse model of IBD resulted in lowering the disease activity index, decreasing colonic inflammatory lesions by 4-fold, and suppressing inflammatory markers (e.g., TNF-alpha, and interferon-gamma) in the gut. Furthermore, studies in LANCL2-/- mice demonstrated that loss of LANCL2 abrogated beneficial actions of 7, suggesting high selectivity for the target. In conclusion, 7 merits continued development as a LANCL2-based, first-in-class orally active therapeutic for IBD.